NextPoint Therapeutics

About:

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients.

Website: https://nextpointtx.com/

Twitter/X: NextPointTX

Top Investors: Invus, Catalio Capital Management, Leaps by Bayer, MPM Capital, Sanofi Ventures

Description:

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Total Funding Amount:

$123M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2020-01-01

Contact Email:

info(AT)nextpointtx.com

Founders:

Gordon Freeman, Xingxing Zang

Number of Employees:

51-100

Last Funding Date:

2024-02-14

IPO Status:

Private

Industries:

© 2025 bioDAO.ai